Endovascular Therapy: Not a Barrier to Effective Stroke Thrombolysis?
"Discover how endovascular stroke treatment complements, not hinders, high thrombolysis rates for acute ischemic stroke patients."
For decades, intravenous recombinant tissue plasminogen activator (IVRTPA) has been the gold standard for acute ischemic stroke (AIS) treatment. Now, with advancements in endovascular stroke treatment (EST), it's crucial to understand how these approaches can work together to optimize patient outcomes.
A recent study conducted at a German academic stroke center sheds light on the impact and significance of IVRTPA in the age of modern EST. The study meticulously analyzed the clinical practice of systemic thrombolysis, evaluating its benchmarks in a setting where EST is readily available. This is vital for stroke centers worldwide aiming to refine their treatment protocols.
The core intent of this research is to demonstrate that high thrombolysis rates, achieved through IVRTPA, are not precluded by the availability of EST. By examining key metrics like door-to-needle times and rates of symptomatic intracranial hemorrhage, the study provides a roadmap for maintaining effective systemic thrombolysis programs, even as endovascular options expand.
IV Thrombolysis Use and Access
Intravenous thrombolysis (IVT) use in acute ischemic stroke has been increasing alongside improvements in door-to-needle times, although smaller hospitals have been observed to use IVT less often or not at all. The cited review suggests mobile stroke units and advanced neuroimaging could expand eligibility by shortening onset-to-treatment times and identifying salvageable penumbra. A separate review describes alteplase as the cornerstone treatment while examining tenecteplase, reteplase, and alteplase at different doses; these sources address evolving treatment and access, rather than providing a single overall utilization statistic.
IV Thrombolysis as Standard Care
Intravenous thrombolysis is described as standard therapy for acute ischemic stroke, with publications confirming a clear treatment benefit. The 2019 guideline update says IV thrombolysis may be reasonable for mild but disabling symptoms when treatment can begin within 3 to 4.5 hours of onset or last-known-well time. A 2025 review describes thrombolytic strategies that include intravenous treatment, bridging therapy, and treatment beyond the conventional time window, reflecting ongoing development of approaches around the established treatment framework.
Milestones in Stroke Thrombolysis
The National Institute of Neurological Disorders and Stroke (NINDS) trial in 1995 formally established recombinant tissue plasminogen activator as an effective stroke treatment, according to a review of the field’s first three decades. Subsequent trials published between 1995 and 2002 included ECASS, ECASS II, and ATLANTIS A/B, which tested a 0-to-6-hour treatment window and were described as technically neutral on their various primary end points. Endovascular therapy also developed in response to the poor prognosis associated with large-vessel occlusion; the historical account notes that concern about basilar artery occlusion prompted Zeumer and colleagues to perform basilar thrombolysis.
Balancing Endovascular and Thrombolytic Stroke Therapies: Key Findings
The retrospective observational cohort analysis included 1,034 patients with suspected AIS presenting at the emergency department in 2014. The study focused on baseline characteristics, reperfusion procedures, IVRTPA eligibility, clinical outcomes, symptomatic intracranial hemorrhage (sICH), and mortality. The study's findings offer critical insights into current stroke treatment efficacy:
- In 69% of patients, a symptomatic AIS diagnosis was confirmed.
- Of those presenting within 4.5 hours of symptom onset, 62% received reperfusion therapy.
- The effective thrombolysis rate, after excluding cases with absolute contraindications for IVRTPA, reached an impressive 82%.
- Notably, sICH occurred in only 1.1% of patients treated with IVRTPA alone, demonstrating a safe profile when administered appropriately.
- The median door-to-needle (DTN) interval was just 30 minutes, showcasing the efficiency of the stroke center's protocols.
Research on Treatment Rates and IVT’s Role
A study on acute ischemic stroke evaluates how meeting emergency-department time targets under standard protocols, together with patient-related risk factors, affects the intravenous thrombolysis rate among patients within the treatment window. A separate narrative review examines neuroinflammation in COVID-19-mediated acute ischemic stroke, focusing on the ACE2/Angiotensin-(1–7)/Mas receptor axis and the NLRP3 inflammasome and their possible roles in brain repair and secondary prevention. Another report, describing a single-center experience at an academic stroke center in Germany, addresses the impact and significance of IV thrombolysis in the era of mechanical thrombectomy.
Barriers and Risks in Thrombolysis
One source identifies presentation outside the 4.5-hour therapeutic window as the primary barrier to intravenous thrombolysis, attributing delays largely to poor public recognition of stroke symptoms and underuse of emergency medical services. Another account says early clinical trials had high rates of intracerebral hemorrhage, a reason thrombolytic therapy was approached cautiously. The NINDS study in 1995 later demonstrated benefits of recombinant tissue plasminogen activator for acute ischemic stroke patients who arrived within the treatment window, as described in a review of thrombolysis limitations.
Comparing Thrombolytic Agents
A 2026 comparison review says the relative efficacy, safety, and optimal dosing of newer thrombolytic agents for acute ischemic stroke within 4.5 hours remain unclear. A 2023 review describes alteplase as the only approved thrombolytic agent for acute ischemic stroke at that time and notes growing interest in alternatives with improved safety, efficacy, or convenience. It identifies tenecteplase as a potential alternative that might be preferred over alteplase, while the available source snippets do not establish a definitive comparative winner.
Implications for Stroke Care in the Era of Advanced Therapies
This research reinforces the continued importance of IVRTPA as a frontline treatment for AIS, even in centers equipped with advanced endovascular capabilities. The key is to optimize the entire stroke care pathway, from rapid diagnosis and assessment to efficient IVRTPA administration and judicious selection of patients for EST.
Extended Windows and Adjunctive Treatment
A perspective on thrombolysis advances highlights extended-window intravenous thrombolysis and adjunctive intra-arterial thrombolysis during thrombectomy as areas of contemporary research. It proposes that future extended-window strategies integrate artificial-intelligence-powered neuroimaging interpretation. A separate review notes interest in using intra-arterial thrombolysis to target residual distal arterial and microvascular occlusions after intravenous thrombolysis and mechanical thrombectomy, where suboptimal outcomes remain common; it describes this as an emerging approach rather than an established benefit.
Real-World Outcomes and Timely Care
A real-world study reports that acute ischemic stroke patients treated with intravenous rt-PA experienced long-term clinical benefits in survival and functional status. A separate study set out to compare long-term outcomes in real-world observational trials between patients treated with intravenous rt-PA and those who were not. In the United Kingdom, the Thrombolysis in Acute Stroke Collaborative (TASC) is described as a national, data-driven improvement programme focused on safe and timely thrombolysis delivery, combining quantitative data with qualitative evidence.
The study emphasizes that high thrombolysis rates and favorable outcomes are achievable with a focus on streamlined protocols, dedicated stroke teams, and careful adherence to established guidelines. Moreover, it highlights the need for ongoing education and training to ensure that all eligible patients receive timely and appropriate reperfusion therapy.
Ultimately, the successful integration of IVRTPA and EST requires a multidisciplinary approach that prioritizes patient safety, efficiency, and evidence-based decision-making. By embracing this holistic strategy, stroke centers can maximize the benefits of both treatment modalities and improve outcomes for patients with acute ischemic stroke.